Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced the initiation of polymer process development and analytical characterization activities by Nanosoft Polymers in support of ONC010, the company’s lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNP) inhibitor. This work includes polymer synthesis optimization, characterization methodology development, molecular weight assessment, purification strategy refinement and manufacturing scalability assessments as part of Onco-Innovations’ chemistry, manufacturing and controls (CMC) strategy.
The company stated that these activities are intended to establish a scalable, reproducible and analytically characterized polymer platform to support future formulation, manufacturing, regulatory and clinical development. Onco-Innovations said Nanosoft’s expertise in polymer science and nanoparticle drug delivery is expected to strengthen the technical foundation of the ONC010 platform while supporting future GMP manufacturing readiness.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco has secured an exclusive worldwide license to patented technology that targets solid tumors.
For more information, see the full press release at https://nnw.fm/BeSoS.
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://nnw.fm/ONNVF.
